Jens Hennecke Joins Delenex Therapeutics AG
News Nov 13, 2013
Delenex Therapeutics AG has announced that it has engaged Jens Hennecke, PhD, as Business and Corporate Development Advisor.
Dr. Jens Hennecke (46) has a strong track record in business development, corporate development and licensing. He brings extensive experience in the negotiation and closing of corporate alliances.
Prior to joining Delenex and building his own business development advisory franchise, he held the position of Senior Vice President Business Development at Micromet, Inc. where he played a key role in establishing partnerships with major pharma companies, as well as in Micromet’s acquisition by Amgen in 2012.
Dr. Hennecke holds a B.Sc. in biology from the University of Göttingen, Germany, and a Ph.D. from the ETH Zurich, Switzerland.
Dr. Thomas Hecht, Executive Chairman of Delenex mentioned, “We are pleased and proud to have attracted Jens with his international experience and strong business development and licensing background. We are convinced that Jens will add to the success of Delenex and spearhead our business development activities to add new partnerships.”
“I am very much looking forward to working with Delenex,” said Dr. Jens Hennecke. “Delenex has a strong pipeline of PENTRA®Bodies and advanced clinical projects, including topical treatments of dermatologic diseases. This provides for significant partnering opportunities beyond Novartis’ exclusive use of the platform for ophthalmic diseases.”
Human Malaria Parasites Grown for the First Time in Dormant FormNews
One of the biggest obstacles to eradicating malaria is a dormant form of the parasite which is resistant to most antimalarial drugs and can reawaken years later, causing disease relapse. Researchers have shown they can grow the dormant parasite in engineered human liver tissue for several weeks, allowing them to closely study how the parasite becomes dormant, what vulnerabilities it may have, and how it springs back to life.READ MORE
Gut Bacteria Latest Ally in Fight Against SepsisNews
Sepsis occurs when the body's response to the spread of bacteria or toxins to the bloodstream damages tissues and organs. The fight against sepsis could get a helping hand from a surprising source: gut bacteria. Researchers found that giving mice particular microbes increased blood levels of immunoglobulin A (IgA) antibodies, which protected against the kind of widespread bacterial invasion that leads to sepsis.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018